International Journal of Endocrinology最新文献

{"title":"<i>KCNJ11</i> rs5219 Gene Polymorphism Is Associated With T2DM in a Population of Bangladesh: A Case-Control Study.","authors":"Amrita Bhowmik, Begum Rokeya, Yearul Kabir","doi":"10.1155/ije/5834412","DOIUrl":"https://doi.org/10.1155/ije/5834412","url":null,"abstract":"<p><p><b>Introduction:</b> As a polygenic disorder, Type 2 diabetes mellitus is a prevalent disease developed by many multigenetic factors, of which multiple genes located on different chromosomes contribute to its susceptibility. The <i>KCNJ11</i> gene is involved in the Kir6.2 proteins that help release insulin from the potassium channels in pancreatic beta cells. Many studies have found that <i>KCNJ11</i> polymorphism is significantly associated with the incidence of T2DM. Therefore, this study was carried out to investigate the association between <i>KCNJ11</i> gene polymorphism and T2DM in the Bangladeshi population. <b>Materials and Methods:</b> In a case-control study (<i>n</i> = 697), 326 nondiabetic controls and 371 diabetic subjects (diagnosed based on American Diabetes Association criteria) were recruited for this study. The serum fasting glucose, lipid profiles, creatinine, alanine aminotransferase (ALT), HbA_1C, and serum insulin level were measured by standard methods. HOMA-B%, HOMA-S%, and HOMA-IR were calculated using HOMA-SIGMA software Version 2.2. A standard formula calculated QUICKI and Secretory-HOMA. The chemical method was used for DNA extraction from whole blood samples. The PCR-RFLP method was used to detect <i>KCNJ11</i> polymorphisms by restriction enzyme (BanII) digestion. As appropriate, data were analyzed using an independent <i>t</i>-test, chi-square, or Fisher exact test. <i>p</i> < 0.05 was considered significant. <b>Results:</b> The frequency of the risk allele K was significantly higher in the T2DM group than control (<i>p</i> ≤ 0.01). The frequency of the KK genotype was higher among the T2DM group (3.77% vs. 1.84%, <i>p</i> < 0.05), and the frequency of the EK genotype was significantly higher among the T2DM than the control group (42.86% vs. 27.91%, <i>p</i> < 0.001). The EE genotype was significantly associated with T2DM in the dominant model EE + EK with an OR of 2.06 (95% CI 1.51-2.82, <i>p</i> ≤ 0.001). <b>Conclusion:</b> This study showed that rs5219 polymorphism of the <i>KCNJ11</i> gene is a significant risk factor for Type 2 diabetes mellitus in the Bangladeshi population.</p>","PeriodicalId":13966,"journal":{"name":"International Journal of Endocrinology","volume":"2025 ","pages":"5834412"},"PeriodicalIF":2.3,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12064312/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144017638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effect of Exenatide on Platelets Ratio Index and Fibrosis-4 Index in Obese Patients With Diabetes Mellitus.","authors":"Gamze Ergun Sezer, Meral Mert","doi":"10.1155/ije/6332117","DOIUrl":"https://doi.org/10.1155/ije/6332117","url":null,"abstract":"<p><p>Many studies have shown a close relationship between type 2 diabetes mellitus and obesity. Glucagon-like peptide-1 (GLP-1) agonists are particularly preferred as antidiabetic medications for obese patients with type 2 diabetes because they not only help with glycemic control but also promote weight loss by slowing gastric emptying. Fatty liver disease, a significant complication of obesity, can progress to hepatic fibrosis and cirrhosis in later stages. Platelets ratio index (APRI), fibrosis-4 index (FIB-4), indices are two of the most studied indirect markers of hepatic fibrosis. Our study aimed to investigate the effect of exenatide, a GLP-1 agonist, on the APRI and FIB-4 indices in obese patients with type 2 diabetes mellitus. We included obese patients with type 2 diabetes treated with exenatide at the endocrinology and metabolism outpatient clinics of Bakırköy Dr. Sadi Konuk Training and Research Hospital between January 2015 and May 2018. We calculated the APRI and FIB-4 indexes retrospectively using data on aspartate aminotransferase, alanine aminotransferase, platelet counts, and ages. The study included 170 patients, with an average age of 48.27 ± 11 years. We compared the APRI and FIB-4 indices at the third and sixth months after the onset of exenatide and before the treatment. While there was no significant change in the FIB-4 index with treatment, the APRI index showed a significant decrease. In conclusion, our study observed a significant decrease in the APRI index with exenatide treatment, while the FIB-4 index remained unchanged. More research is needed on liver fibrosis indices in the obese population.</p>","PeriodicalId":13966,"journal":{"name":"International Journal of Endocrinology","volume":"2025 ","pages":"6332117"},"PeriodicalIF":2.3,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12052462/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143986360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel Model Predicts Type 2 Diabetes Mellitus Patients Complicated With Metabolic Syndrome Using Retrospective Dataset From First Affiliated Hospital of Shenzhen University, China.","authors":"Jinghua Lai, Mingyu Hao, Xiaohong Huang, Shujuan Chen, Dewen Yan, Haiyan Li","doi":"10.1155/ije/9558141","DOIUrl":"https://doi.org/10.1155/ije/9558141","url":null,"abstract":"<p><p><b>Objective:</b> Metabolic syndrome (MS) is the most important risk factor for Type 2 diabetes mellitus (T2DM) and cardiovascular disease. This study used a retrospective dataset from the First Affiliated Hospital of Shenzhen University and aimed to develop and validate a novel model nomogram based on clinical parameters to predict MS in patients with T2DM. <b>Methods:</b> A total of 2854 patients with T2DM between January 2014 and May 2022 were selected and divided into a training dataset (<i>n</i> = 2114) and a validation dataset (<i>n</i> = 740). This study used multivariate logistic regression analysis to develop a nomogram for predicting MS in patients with T2DM that included candidates selected in the LASSO regression model. The data were set standardized before LASSO regression. The area under the receiver operating characteristic curve (AUC-ROC) was used to assess discrimination in the prediction model. The calibration curve is used to evaluate the calibration of the calibration nomogram, and the clinical decision curve is used to determine the clinical utility of the calibration diagram. The validation dataset is used to evaluate the performance of predictive models. <b>Results:</b> A total of 2854 patients were eligible for this study. There were 1941 (68.01%) patients with MS. The training dataset included 20 potential risk factors of the patient's demographic, clinical, and laboratory indexes in the LASSO regression analysis. Gender, hypertension, BMI, WC, HbA1c, TG, LDL, and HDL were multivariate models. We obtained a model for estimating MS in patients with T2DM. The AUC-ROC of the training dataset in our model is 0.886, and the 95% CI is 0.871-0.901. Similar to the results obtained from the training dataset, the AUC-ROC of the validation dataset in our model is 0.859, and the 95% CI is 0.831-0.887, thus proving the robustness of the model. The prediction model is as follows: logit (MS) = -9.18209 + 0.14406 ∗ BMI (kg/m²) + 0.09218 ∗ WC (cm) + 1.05761 ∗ TG (mmol/L)-3.30013 ∗ HDL (mmol/L). The calibration plots of the predicted probabilities show excellent agreement with the observed MS rates. Decision curve analysis demonstrated that the new nomogram provided significant net benefits in clinical applications. <b>Conclusion:</b> The prediction model of this study covers four clinically easily obtained parameters: BMI, WC, TG, and HDL, and shows a high accuracy rate in the validation dataset. Our predictive model may provide an effective method for large-scale epidemiological studies of T2DM patients with MS and offer a practical tool for the early detection of MS in clinical work.</p>","PeriodicalId":13966,"journal":{"name":"International Journal of Endocrinology","volume":"2025 ","pages":"9558141"},"PeriodicalIF":2.3,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12045690/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144011452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Composite Dietary Antioxidant Index With the Risk of Nonalcoholic Fatty Liver Disease and All-Cause and Cause-Specific Mortality: Evidence From NHANES 2001-2018.","authors":"Yingchao Ding, Miaomiao Fan, Chen Jiang, Naixin Dou, Yaqi Guo, Xiaolin Zhao, Xin Sun, Chunxiao Yu, Qingbo Guan","doi":"10.1155/ije/3255533","DOIUrl":"https://doi.org/10.1155/ije/3255533","url":null,"abstract":"<p><p>Evidence regarding the associations of composite dietary antioxidant index (CDAI) with the risk of prevalence and mortality of nonalcoholic fatty liver disease (NAFLD) is limited. We aimed to investigate these relationships using data from the National Health and Nutrition Examination Survey (NHANES). A total of 19,404 individuals with a mean age of 50.10 years were included. In multivariate-adjusted logistic regression analysis, compared to those in the lowest quartile of CDAI, individuals with the highest quartile were negatively associated with NAFLD prevalence (OR: 0.85, 95% CI: 0.75, 0.96), and the dose-response curve exhibited a linear relationship. Moreover, multivariate-adjusted Cox regression revealed that individuals with the highest quartile were negatively associated with cancer mortality (HR: 0.61, 95% CI: 0.37, 0.99) compared to those with the lowest quartile of CDAI in NAFLD patients. Moreover, the dose-response analysis demonstrated that CDAI had a nonlinear association with all-cause mortality in NAFLD patients. Multiple stratified and sensitivity analyses demonstrated that these associations are stable. CDAI was protective against the prevalence and cancer mortality of NAFLD. These results may provide new insights into adapting CDAI as a dietary strategy to prevent and improve the prognosis of NAFLD.</p>","PeriodicalId":13966,"journal":{"name":"International Journal of Endocrinology","volume":"2025 ","pages":"3255533"},"PeriodicalIF":2.3,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12031604/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144063718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Empagliflozin on Serum Levels of Thyroid Hormones Among Prediabetic and Diabetic Patients.","authors":"Mojgan Sanjari, Narges Sadeghi, Ladan Amirkhosravi, Mohammad Hadavizadeh, Ahmad Naghibzadeh-Tahami, Zohreh Safi","doi":"10.1155/ije/9920286","DOIUrl":"https://doi.org/10.1155/ije/9920286","url":null,"abstract":"<p><p><b>Objectives:</b> Thyroid dysfunction (TD) and diabetes mellitus (DM) are the most prevalent chronic endocrine disorders that often coexist. Thyroid hormone affects glucose homeostasis through different mechanisms. SGLT2 inhibitors are a drug class used to treat diabetes. However, the effect of this drug class on thyroid tests has not been investigated among diabetic patients. Therefore, the current study aims to assess the effect of empagliflozin on thyroid tests. <b>Materials and Methods:</b> This quasi-experimental study was conducted on 44 prediabetic and type 2 diabetic patients aged 18-65, directed to the clinic affiliated to Kerman Medical Sciences University in 2022-2023. Diabetic patients with HbA1c level of 0.5%-1% higher than the therapeutic target, who did not take blood sugar control drugs, were included in the study. All the patients received 10 mg of empagliflozin once daily for 3 months. Before and 3 months after taking empagliflozin, changes in TSH, total T4, and total T3 serum levels were measured. <b>Results:</b> The mean patients' age was 54.77 years old. The mean FBS and HbA1c levels decreased 3 months after taking empagliflozin (<i>p</i> < 0.05). After taking empagliflozin, T3 level as well as T3/T4 ratio increased (<i>p</i>=0.001). However, no significant change was observed in T4 and TSH levels (<i>p</i> > 0.05). Also, level of T3 significantly changed with changes in weight and triglyceride level after taking empagliflozin. <b>Conclusion:</b> The results showed taking empagliflozin could increase T3 level as well as T3/T4 ratio. However, it had no effect on total T4 and TSH levels. <b>Trial Registration:</b> Iranian Registry of Clinical Trials (IRCT): IRCT20090317001774N10.</p>","PeriodicalId":13966,"journal":{"name":"International Journal of Endocrinology","volume":"2025 ","pages":"9920286"},"PeriodicalIF":2.3,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12021486/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143964461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Visceral Adiposity Index Is Associated With the Development of Increased Urinary Albumin Excretion and Chronic Kidney Disease: A Population-Based Study.","authors":"Junyan Yu, Chulin Huang, Jiabin Lin, Diaozhu Lin, Feng Li, Yiqin Qi, Ying Liang, Chuan Wang, Leiqin Cai, Wanting Feng, Na Li, Guojuan Lao, Huisheng Xiao, Chuan Yang, Li Yan, Meng Ren, Kan Sun","doi":"10.1155/ije/1173231","DOIUrl":"10.1155/ije/1173231","url":null,"abstract":"<p><p><b>Background:</b> In recent years, the impact of visceral fat accumulation on renal damage has garnered significant attention. However, whether visceral fat accumulation contributes to the incidence of both albuminuria and chronic kidney disease (CKD) is still uncertain. Our objective is to look into the possible correlation between visceral adiposity accumulation and incident increased urinary albumin excretion and CKD. <b>Methods:</b> We analyzed data from a cohort of 9916 subjects aged 40 years and above. As an innovative and convenient biomarker of visceral adiposity distribution, visceral adiposity index (VAI) was calculated in accordance with a gender-specific equation using measurement of blood lipids and anthropometric parameters of obesity. Albuminuria was determined by urine albumin-to-creatinine ratio (UACR) ≥ 30 mg/g. CKD was determined by establishment of either of the following: (1) estimated glomerular filtration rate (eGFR) 60 mL/min per 1.73 m² or less; (2) UACR ≥ 30 mg/g. <b>Results:</b> During an average follow-up period of 3.6 ± 0.7 years, 245 (4.7%) subjects developed albuminuria and 332 (6.3%) participants developed CKD. Incidence of albuminuria and CKD had a tendency to advance along with ascending VAI levels in both genders. According to multiple stepwise linear regression analysis, γ-glutamyltransferase (γ-GGT), fasting insulin, fasting plasma glucose (FPG), low-density lipoprotein cholesterol (LDL-C), and systolic blood pressure (SBP) were independent determinants for VAI. Multivariate-adjusted hazard ratios (HRs) of albuminuria with 95% confidence intervals (CIs) in Cox regression analysis were 1 (reference), 0.82 (0.53-1.29), 1.50 (1.01-2.23), and 1.52 (1.02-2.26) in ascending quartiles of VAI. Similarly, the HRs with 95% CI of CKD in ascending quartiles of VAI were 1 (reference), 0.96 (0.66-1.41), 1.51 (1.07-2.15), and 1.56 (1.10-2.20). For subgroup analyses, VAI significantly correlated with risk of both albuminuria and CKD in older subjects (age ≥ 58 years), nondiabetes subjects, and non-ASCVD subjects (all <i>p</i> < 0.05). <b>Conclusions:</b> The greater deposition of visceral fat assessed by VAI is independently associated with risk of increased urinary albumin excretion and CKD in middle-aged and aged Chinese.</p>","PeriodicalId":13966,"journal":{"name":"International Journal of Endocrinology","volume":"2025 ","pages":"1173231"},"PeriodicalIF":2.3,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12446585/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145112927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Association Between Estrogen-Containing Oral Contraceptive Pills and Hypothyroidism.","authors":"Lama Alkahlout, Shahd Hamran, Nour Darwish, Yara Dweidri, Giridhara R Babu, Rafif Mahmood Al Saady","doi":"10.1155/ije/5978558","DOIUrl":"10.1155/ije/5978558","url":null,"abstract":"<p><p><b>Background:</b> Hypothyroidism is an endocrine disorder that affects 10 times more females than males, with substantial health impacts. The role of estrogen-containing oral contraceptives (OCPs) in influencing thyroid function remains relatively underexplored. This study investigated the association between estrogen-containing OCP use and hypothyroidism in the female population in Qatar. <b>Methods:</b> We utilized data from the Qatar Biobank to conduct a cross-sectional study of 1001 female participants with a current or previous history of estrogen-containing OCP use. The thyroid function of the participants was evaluated via thyroid function test parameters (thyroid stimulating hormone (TSH) and free tetraiodothyronine (fT4)) as outcomes, and sex hormone-binding globulin (SHBG) levels as a proxy indicator of OCP use. We adjusted for confounders such as age, ethnicity, and type 2 diabetes mellitus status via multivariable logistic regression to determine the odds of hypothyroidism associated with SHBG levels. <b>Results:</b> Among the 1001 participants, 34 (3.4%) met the diagnostic criteria for hypothyroidism. Multinomial logistic regression revealed no increased odds of hypothyroidism at the 90th percentile cutoff for SHBG levels (OR 1.00, 95% CI 0.29-3.50). However, at the 95th percentile of SHBG values, there was 46% higher odds of hypothyroidism (OR 1.46, 95% CI 0.33-6.54) and an over tenfold increase at the 99th percentile (OR 10.07, 95% CI 1.94-52.45, <i>p</i>=0.006). Other variables, such as age, ethnicity, and diabetes status, were not associated with SHBG levels. Non-Qatari Arabs had higher odds of hypothyroidism compared with that of Qataris (OR 8.06, 95% CI 0.84-77.54, <i>p</i> value 0.071). <b>Conclusion:</b> This study offers evidence that SHBG levels can be used to indicate estrogen-containing OCP use. Furthermore, higher SHBG levels are associated with higher odds of hypothyroidism among OCP users, and the odds of hypothyroidism vary across different ethnicities. These findings highlight the need for further research to explore the mechanisms linking OCP use to thyroid dysfunction and to investigate other potential risk factors.</p>","PeriodicalId":13966,"journal":{"name":"International Journal of Endocrinology","volume":"2025 ","pages":"5978558"},"PeriodicalIF":2.3,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11936525/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143709628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Insulin Requirement Profiles of Short-Term Continuous Subcutaneous Insulin Infusion Therapy in Patients With Type 2 Diabetic Nephropathy.","authors":"Qianqiu Feng, Biyun Li, Jiating Lin, Li Zou, Wen Xu, Longyi Zeng, Ping Li, Shuo Lin","doi":"10.1155/ije/8403917","DOIUrl":"10.1155/ije/8403917","url":null,"abstract":"<p><p><b>Objective:</b> This study aimed to explore the insulin requirement during continuous subcutaneous insulin infusion (CSII) treatment in patients with type 2 diabetic kidney disease (T2DKD). <b>Methods:</b> This study retrospectively analyzed the clinical data of 150 T2DKD patients in the Department of Endocrinology and Metabolism of the Third Affiliated Hospital of Sun Yat-sen University from January 2018 to December 2021. All patients received short-term CSII treatment and achieved the blood glucose target by adjusting insulin infusion. The patients' daily insulin requirements during the treatment were recorded and analyzed. <b>Result:</b> There were 91 males and 59 females with an average age of 60.6 ± 10.6 years. Total daily insulin dose (TDD), total daily insulin dose per kilogram (TDD kg^-1), total basal insulin dose per kilogram (TBa kg^-1), and total bolus insulin dose per kilogram (TBo kg^-1) fell with the decline of eGFR when achieving the blood glucose target except for the ratio of total basal insulin dose (TBD) to TDD (%TBa). Insulin requirement was less in patients with eGFR < 60 mL/min/1.73 m² compared to those with eGFR ≥ 60 mL/min/1.73 m² (<i>p</i> < 0.05). When achieving the blood glucose target, eGFR ≥ 60 mL/min/1.73 m² group and eGFR < 60 mL/min/1.73 m² group were 0.71 ± 0.19 U/kg and 0.60 ± 0.24 U/kg, respectively. Multiple linear regression analyses showed that glycated hemoglobin and eGFR were independent factors associated with TDD kg^-1. <b>Conclusion:</b> In patients with T2DKD who received short-term CSII therapy, the insulin requirement decline with the decrease of eGFR, while the %TBa did not change significantly. The dosage of insulin should be adjusted according to the level of eGFR in patients with T2DKD treated with CSII.</p>","PeriodicalId":13966,"journal":{"name":"International Journal of Endocrinology","volume":"2025 ","pages":"8403917"},"PeriodicalIF":2.3,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11925604/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143669757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigation of Potential Targets for Bupleuri Radix in the Treatment of Subacute Thyroiditis.","authors":"Xiaoli Lei, Lina Lv, Yongsheng Ma, Chenda Zhang, Li Li, Yanqin Huang","doi":"10.1155/ije/7460422","DOIUrl":"https://doi.org/10.1155/ije/7460422","url":null,"abstract":"<p><p><b>Objective:</b> This study aimed to reveal the underlying mechanism of Radix Bupleuri in the treatment of subacute thyroiditis (SAT). <b>Methods:</b> Radix Bupleuri, a key herb in traditional Chinese medicine (TCM) for over two millennia, is widely used to treat exterior syndromes, dissipate heat, harmonize liver Qi, and invigorate Yang-Qi. It is also commonly prescribed for SAT. To understand its molecular mechanisms, we collected active components and their targets from databases such as TCMSP, SwissADME, and Swiss TargetPrediction. Radix Bupleuri SAT genes were sourced from GeneCards, OMIM, and DisGeNET databases. By analyzing these data sources together, we identified the relevant ingredients of Radix Bupleuri for treating SAT. Using Cytoscape 3.7.1 software, we selected core proteins to construct an ingredient-target-pathway network. Molecular docking and visualization were performed with AutoDock Vina and Discovery Studio tools, respectively. The stability of the binding model was confirmed through molecular dynamics (MD) simulation techniques. To further validate the causal relationship between CDK4 gene in the GWAS database and SAT in the FinnGen database, we conducted a two-sample Mendelian randomization analysis. <b>Results:</b> Through active ingredient-target network screening, 8 key active ingredients and 10 core targets were identified. The strongest binding was observed between cubebin/quercetin and CDK4 with a binding energy of ≤ -9.2 kcal·mol^-1, whereas isorhamnetin/quercetin showed stable binding with PIK3CA. The stability of cubebin binding with CDK4 was confirmed through MD simulation, indicating that CDK4 potentially modulates SAT by regulating cell cycle progression, cellular proliferation, immune responses, and inflammatory reactions. <b>Conclusion:</b> Radix Bupleuri may affect SAT by its action on CDK4, providing scientific basis for further clinical application of Radix Bupleuri in the treatment of SAT.</p>","PeriodicalId":13966,"journal":{"name":"International Journal of Endocrinology","volume":"2025 ","pages":"7460422"},"PeriodicalIF":2.3,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11985236/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143997990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Resmetirom: The First Disease-Specific Treatment for MASH.","authors":"Ali Mohamed Mousa, Mervat Mahmoud, Ghaida Mubarak AlShuraiaan","doi":"10.1155/ije/6430023","DOIUrl":"https://doi.org/10.1155/ije/6430023","url":null,"abstract":"<p><p>In 2023, the medical terminology for Nonalcoholic Fatty Liver Disease (NAFLD) and NA SteatoHepatitis (NASH) was updated to Metabolic Dysfunction-Associated SteatoticLiver Disease (MASLD) and MA SteatoHepatitis (MASH). This review highlights the critical epidemiological, pathophysiological, and therapeutic aspects of MASH, focusing on the novel treatment option, resmetirom. Resmetirom, a thyroid hormone receptor-beta (THR-β) agonist, specifically targets liver function to simulate localized hyperthyroidism, effectively reducing lipid accumulation and liver fibrosis without the systemic effects commonly associated with thyroid hormone therapy. Clinical trials, particularly the pivotal MAESTRO-NASH trial, have demonstrated significant improvements in liver health metrics, achieving primary endpoints by resolving MASH without worsening fibrosis and showing a favorable safety profile. This paper reviews the mechanism of action, efficacy, and safety of resmetirom, providing insight into its potential to change the therapeutic landscape for patients suffering from MASH.</p>","PeriodicalId":13966,"journal":{"name":"International Journal of Endocrinology","volume":"2025 ","pages":"6430023"},"PeriodicalIF":2.3,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11985219/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144012184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}